<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03102762</url>
  </required_header>
  <id_info>
    <org_study_id>1232017</org_study_id>
    <nct_id>NCT03102762</nct_id>
  </id_info>
  <brief_title>Botulinum Toxin for Erectile Dysfunction</brief_title>
  <official_title>Intracavernosal Injection of Botulinum Toxin Type A in the Treatment of Erectile Dysfunction (Phase 2 Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and efficacy of intra-cavernosal Botulinum toxin injection as an
      alternative line of treatment in patients with erectile dysfunction - not responding to oral
      PDE5i - through cavernosal smooth muscle relaxation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The initial Phase 1 study demonstrated safety and efficacy of Botulinum toxin type A in the
      treatment of Erectile dysfunction in a small randomized controlled trial of 24 men.

      The investigators conduct a phase 2 trial to confirm the initial results in a larger group of
      men.70 males will be included in the study. The participants will be subjected for full
      history taking, general and genital examination. Penile duplex will be performed to assess a
      vascular etiology before the treatment and 2 weeks later. The patients will be randomized
      into a treatment group (35 patients) and a control group (35 patients).

      All patients will sign an informed consent. The treatment group will be injected IC with a
      trimix solution (20 ug alprostadil + 1 mg phentolamine + 30 mg papaverine) for color Doppler
      assessment, followed, next day by 50 units of BTX-A. The control group will be injected with
      the trimix solution during penile color Doppler assessment followed next day with a normal
      saline injection. The erection hardness score (EHS) will be assessed during the Doppler exam.

      Procedure: At least 1 day after the penile color Doppler test, the patient is placed in the
      supine position flaccid and stretched penile length and girth would be measured from tip of
      the penis to the pubic bone will be done. A rubber band will be applied to the base of the
      penis. The skin will be prepped with alcohol swabs followed by the IC injection of 100 units
      of BTX-A. Direct pressure will be applied for 2 minutes. The rubber band will be removed
      after 15 minutes.

      Patients and controls will fill the Sexual Health Inventory for men (SHIM) questionnaire and
      answer the the Sexual Encounter Profile questions 1 and 2 (SEP 2 &amp; SEP 3), and the global
      assessment question (GAQ) before and 4 weeks after treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 3, 2017</start_date>
  <completion_date type="Actual">January 10, 2019</completion_date>
  <primary_completion_date type="Actual">January 10, 2019</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Prospective, randomized double blind placebo control ( RDBPC) study.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Right (PSV R) and Left (PSV L) Cavernosal Artery Mean PSV Before Treatment</measure>
    <time_frame>Baseline</time_frame>
    <description>Baseline mean Peak systolic velocity (PSV) in the Cavernosal arteries, on color Doppler examination, in the patient and control groups.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Right (PSV R) and Left (PSV L) Cavernosal Artery Mean PSV After Treatment</measure>
    <time_frame>2 weeks</time_frame>
    <description>Cavernosal artery mean peak systolic velocity (PSV) after treatment, on color Doppler examination, in the patient and control groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>SHIM Score Before Treatment</measure>
    <time_frame>Baseline</time_frame>
    <description>Assessment of the Sexual Health Inventory for men (SHIM) questionnaire before treatment for both groups. It is a questionnaire that helps asses if the patient has erectile dysfunction (ED) and assesses its degree. Results range from 1 to 25. A score of 1-7 denotes Severe ED, 8-11 Moderate ED, 12-16, Mild to Moderate ED, 17-21 Mild ED, 22-25 No ED.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SHIM Score After Treatment</measure>
    <time_frame>2 weeks after injection.</time_frame>
    <description>Assessment of the Sexual Health Inventory for men (SHIM) questionnaire after treatment for both groups. It is a questionnaire that helps to asses if the patient has erectile dysfunction (ED) and to assess its degree. Results range from 1 to 25. A score of 1-7 denotes Severe ED, 8-11 Moderate ED, 12-16, Mild to Moderate ED, 17-21 Mild ED, 22-25 No ED.
Minimum value is 1, Maximum value is 25, the higher the score the better is the outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SHIM Score After Treatment</measure>
    <time_frame>6 and 12 weeks after injection.</time_frame>
    <description>Assessment of the Sexual Health Inventory for men (SHIM) questionnaire after 6 and 12 weeks of both groups. It is a questionnaire that helps to asses if the patient has erectile dysfunction (ED) and to assess its degree. Results range from 1 to 25. A score of 1-7 denotes Severe ED, 8-11 Moderate ED, 12-16, Mild to Moderate ED, 17-21 Mild ED, 22-25 No ED.
Minimum value is 1, Maximum value is 25, the higher the score the better is the outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Penile Size Before Treatment</measure>
    <time_frame>Baseline</time_frame>
    <description>Measurement of penile length before treatment:
Flaccid, stretched and erect penile length.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Penile Size After Treatment</measure>
    <time_frame>2 weeks after injection.</time_frame>
    <description>Measurement of penile length after treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Penile Size After Treatment</measure>
    <time_frame>6 and 12 weeks after injection.</time_frame>
    <description>Measurement of penile length after treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intra-vaginal Latency Time Before Treatment</measure>
    <time_frame>Baseline</time_frame>
    <description>Measurement of the duration of intercourse from intromission to ejaculation before treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intra-vaginal Latency Time After Treatment</measure>
    <time_frame>2 weeks after injection.</time_frame>
    <description>Measurement of the duration of intercourse from intromission to ejaculation after treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intra-vaginal Latency Time After Treatment</measure>
    <time_frame>6 and 12 weeks after injection.</time_frame>
    <description>Measurement of the duration of intercourse from intromission to ejaculation after treatment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Sexual Dysfunction</condition>
  <condition>Erectile Dysfunction</condition>
  <arm_group>
    <arm_group_label>Botulinum Toxin Type A (BTX-A) Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental: BTX-A Group The treatment group, 35 patients, will be injected with 100 units BTX-A one day following penile colour Doppler assessment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline Group:
The control group, 35 patients, will be injected with 1 ml normal saline one day following penile colour Doppler assessment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Botulinum Toxin Type A</intervention_name>
    <description>Drug: Botulinum Toxin Type A The treatment group will be injected with 100 units BTX-A one day following penile colour doppler assessment.</description>
    <arm_group_label>Botulinum Toxin Type A (BTX-A) Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>The treatment group will be injected with 1 ml normal saline one day following penile colour doppler assessment.</description>
    <arm_group_label>Placebo Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  70 males will be included in the study recruited from Andrology, Sexology &amp; STD's
             outpatient clinic, Kasr El Aini Hospitals, Cairo University, complaining of ED.

          -  Unable to develop erections sufficient for intercourse.

          -  Failing to respond to first line and second line treatments for Erectile Dysfunction
             with surgery as the only remaining treatment option.

          -  Age between 18 to 80 years.

        Exclusion Criteria:

        - Significant cardiovascular disease interfering with sexual activity
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Islam M Fathy, MD</last_name>
    <role>Study Director</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Abdelrahman A Hassan, Msc</last_name>
    <role>Study Director</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Andrology, Cairo University</name>
      <address>
        <city>Cairo</city>
        <zip>11231</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <link>
    <url>https://clinicaltrials.gov/ct2/show/record/NCT02584686</url>
    <description>Botulinum Toxin Type A and Erectile Dysfunction (Phase 1 study)</description>
  </link>
  <reference>
    <citation>Ghanem H, Soliman I, AbdulHamid M, et. PS-08-016 Can intracavernosal botulinum toxin injection salvage vascular erectile dysfunction patients not responding to oral and intracavernous therapy? A pilot study. May 2016. Volume 13, Issue 5, Supplement 2, Page S116.</citation>
  </reference>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>March 28, 2017</study_first_submitted>
  <study_first_submitted_qc>April 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 6, 2017</study_first_posted>
  <results_first_submitted>March 17, 2019</results_first_submitted>
  <results_first_submitted_qc>November 16, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">December 5, 2019</results_first_posted>
  <last_update_submitted>December 23, 2019</last_update_submitted>
  <last_update_submitted_qc>December 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Hussein Ghanem</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Erectile dysfunction</keyword>
  <keyword>Botulinum toxin A</keyword>
  <keyword>Botox</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erectile Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 3, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/62/NCT03102762/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>BTX-A Group</title>
          <description>Experimental: BTX-A Group The treatment group, 35 patients, will be injected with 100 units BTX-A one day following penile colour Doppler assessment.
Botulinum Toxin Type A: Drug: Botulinum Toxin Type A The treatment group will be injected with 100 units BTX-A one day following penile colour doppler assessment.</description>
        </group>
        <group group_id="P2">
          <title>Placebo Group</title>
          <description>Saline Group:
The control group, 35 patients, will be injected with 1 ml normal saline one day following penile colour Doppler assessment.
Normal saline: The treatment group will be injected with 1 ml normal saline one day following penile colour doppler assessment.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>One patient was dropped out from the treatment group 6 weeks after of BTX injection.</population>
      <group_list>
        <group group_id="B1">
          <title>BTX-A Group</title>
          <description>Experimental: BTX-A Group The treatment group, 35 patients, will be injected with 100 units BTX-A one day following penile colour Doppler assessment.
Botulinum Toxin Type A: Drug: Botulinum Toxin Type A The treatment group will be injected with 100 units BTX-A one day following penile colour doppler assessment.</description>
        </group>
        <group group_id="B2">
          <title>Placebo Group</title>
          <description>Saline Group:
The control group, 35 patients, will be injected with 1 ml normal saline one day following penile colour Doppler assessment.
Normal saline: The treatment group will be injected with 1 ml normal saline one day following penile colour doppler assessment.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="35"/>
            <count group_id="B2" value="35"/>
            <count group_id="B3" value="70"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="63"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.26" spread="7.8"/>
                    <measurement group_id="B2" value="56" spread="9.12"/>
                    <measurement group_id="B3" value="55.13" spread="8.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Egyptian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Egypt</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Right (PSV R) and Left (PSV L) Cavernosal Artery Mean PSV Before Treatment</title>
        <description>Baseline mean Peak systolic velocity (PSV) in the Cavernosal arteries, on color Doppler examination, in the patient and control groups.</description>
        <time_frame>Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BTX-A Group</title>
            <description>Experimental: BTX-A Group The treatment group, 35 patients, will be injected with 100 units BTX-A one day following penile colour Doppler assessment.
Botulinum Toxin Type A: Drug: Botulinum Toxin Type A The treatment group will be injected with 100 units BTX-A one day following penile colour doppler assessment.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Saline Group:
The control group, 35 patients, will be injected with 1 ml normal saline one day following penile colour Doppler assessment.
Normal saline: The treatment group will be injected with 1 ml normal saline one day following penile colour doppler assessment.</description>
          </group>
        </group_list>
        <measure>
          <title>Right (PSV R) and Left (PSV L) Cavernosal Artery Mean PSV Before Treatment</title>
          <description>Baseline mean Peak systolic velocity (PSV) in the Cavernosal arteries, on color Doppler examination, in the patient and control groups.</description>
          <units>cm/sec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PSV R</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.52" spread="12.15"/>
                    <measurement group_id="O2" value="30.85" spread="15.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PSV L</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.33" spread="11.21"/>
                    <measurement group_id="O2" value="31.73" spread="15.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Right (PSV R) and Left (PSV L) Cavernosal Artery Mean PSV After Treatment</title>
        <description>Cavernosal artery mean peak systolic velocity (PSV) after treatment, on color Doppler examination, in the patient and control groups.</description>
        <time_frame>2 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BTX-A Group</title>
            <description>Experimental: BTX-A Group The treatment group, 35 patients, will be injected with 100 units BTX-A one day following penile colour Doppler assessment.
Botulinum Toxin Type A: Drug: Botulinum Toxin Type A The treatment group will be injected with 100 units BTX-A one day following penile colour doppler assessment.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Saline Group:
The control group, 35 patients, will be injected with 1 ml normal saline one day following penile colour Doppler assessment.
Normal saline: The treatment group will be injected with 1 ml normal saline one day following penile colour doppler assessment.</description>
          </group>
        </group_list>
        <measure>
          <title>Right (PSV R) and Left (PSV L) Cavernosal Artery Mean PSV After Treatment</title>
          <description>Cavernosal artery mean peak systolic velocity (PSV) after treatment, on color Doppler examination, in the patient and control groups.</description>
          <units>cm/sec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PSV R</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.68" spread="13.27"/>
                    <measurement group_id="O2" value="31.67" spread="15.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PSV L</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.015" spread="13.03"/>
                    <measurement group_id="O2" value="32.09" spread="16.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SHIM Score Before Treatment</title>
        <description>Assessment of the Sexual Health Inventory for men (SHIM) questionnaire before treatment for both groups. It is a questionnaire that helps asses if the patient has erectile dysfunction (ED) and assesses its degree. Results range from 1 to 25. A score of 1-7 denotes Severe ED, 8-11 Moderate ED, 12-16, Mild to Moderate ED, 17-21 Mild ED, 22-25 No ED.</description>
        <time_frame>Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BTX-A Group</title>
            <description>Experimental: BTX-A Group The treatment group, 35 patients, will be injected with 100 units BTX-A one day following penile colour Doppler assessment.
Botulinum Toxin Type A: Drug: Botulinum Toxin Type A The treatment group will be injected with 100 units BTX-A one day following penile colour doppler assessment.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Saline Group:
The control group, 35 patients, will be injected with 1 ml normal saline one day following penile colour Doppler assessment.
Normal saline: The treatment group will be injected with 1 ml normal saline one day following penile colour doppler assessment.</description>
          </group>
        </group_list>
        <measure>
          <title>SHIM Score Before Treatment</title>
          <description>Assessment of the Sexual Health Inventory for men (SHIM) questionnaire before treatment for both groups. It is a questionnaire that helps asses if the patient has erectile dysfunction (ED) and assesses its degree. Results range from 1 to 25. A score of 1-7 denotes Severe ED, 8-11 Moderate ED, 12-16, Mild to Moderate ED, 17-21 Mild ED, 22-25 No ED.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4" spread="1.67"/>
                    <measurement group_id="O2" value="5.69" spread="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SHIM Score After Treatment</title>
        <description>Assessment of the Sexual Health Inventory for men (SHIM) questionnaire after treatment for both groups. It is a questionnaire that helps to asses if the patient has erectile dysfunction (ED) and to assess its degree. Results range from 1 to 25. A score of 1-7 denotes Severe ED, 8-11 Moderate ED, 12-16, Mild to Moderate ED, 17-21 Mild ED, 22-25 No ED.
Minimum value is 1, Maximum value is 25, the higher the score the better is the outcome.</description>
        <time_frame>2 weeks after injection.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BTX-A Group</title>
            <description>Experimental: BTX-A Group The treatment group, 35 patients, will be injected with 100 units BTX-A one day following penile colour Doppler assessment.
Botulinum Toxin Type A: Drug: Botulinum Toxin Type A The treatment group will be injected with 100 units BTX-A one day following penile colour doppler assessment.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Saline Group:
The control group, 35 patients, will be injected with 1 ml normal saline one day following penile colour Doppler assessment.
Normal saline: The treatment group will be injected with 1 ml normal saline one day following penile colour doppler assessment.</description>
          </group>
        </group_list>
        <measure>
          <title>SHIM Score After Treatment</title>
          <description>Assessment of the Sexual Health Inventory for men (SHIM) questionnaire after treatment for both groups. It is a questionnaire that helps to asses if the patient has erectile dysfunction (ED) and to assess its degree. Results range from 1 to 25. A score of 1-7 denotes Severe ED, 8-11 Moderate ED, 12-16, Mild to Moderate ED, 17-21 Mild ED, 22-25 No ED.
Minimum value is 1, Maximum value is 25, the higher the score the better is the outcome.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.66" spread="2.17"/>
                    <measurement group_id="O2" value="6.11" spread="2.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SHIM Score After Treatment</title>
        <description>Assessment of the Sexual Health Inventory for men (SHIM) questionnaire after 6 and 12 weeks of both groups. It is a questionnaire that helps to asses if the patient has erectile dysfunction (ED) and to assess its degree. Results range from 1 to 25. A score of 1-7 denotes Severe ED, 8-11 Moderate ED, 12-16, Mild to Moderate ED, 17-21 Mild ED, 22-25 No ED.
Minimum value is 1, Maximum value is 25, the higher the score the better is the outcome.</description>
        <time_frame>6 and 12 weeks after injection.</time_frame>
        <population>One patient was dropped out after 2 weeks of injection from the BTX-A Group</population>
        <group_list>
          <group group_id="O1">
            <title>Botulinum Toxin Type A (BTX-A) Group</title>
            <description>Experimental: BTX-A Group The treatment group, 35 patients, will be injected with 100 units BTX-A one day following penile colour Doppler assessment.
Botulinum Toxin Type A: Drug: Botulinum Toxin Type A The treatment group will be injected with 100 units BTX-A one day following penile colour doppler assessment.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Saline Group:
The control group, 35 patients, will be injected with 1 ml normal saline one day following penile colour Doppler assessment.
Normal saline: The treatment group will be injected with 1 ml normal saline one day following penile colour doppler assessment.</description>
          </group>
        </group_list>
        <measure>
          <title>SHIM Score After Treatment</title>
          <description>Assessment of the Sexual Health Inventory for men (SHIM) questionnaire after 6 and 12 weeks of both groups. It is a questionnaire that helps to asses if the patient has erectile dysfunction (ED) and to assess its degree. Results range from 1 to 25. A score of 1-7 denotes Severe ED, 8-11 Moderate ED, 12-16, Mild to Moderate ED, 17-21 Mild ED, 22-25 No ED.
Minimum value is 1, Maximum value is 25, the higher the score the better is the outcome.</description>
          <population>One patient was dropped out after 2 weeks of injection from the BTX-A Group</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>6 weeks after injection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.97" spread="5.92"/>
                    <measurement group_id="O2" value="5.77" spread="1.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 weeks after injection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.26" spread="4.07"/>
                    <measurement group_id="O2" value="5.57" spread="1.399"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Penile Size Before Treatment</title>
        <description>Measurement of penile length before treatment:
Flaccid, stretched and erect penile length.</description>
        <time_frame>Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BTX-A Group</title>
            <description>Experimental: BTX-A Group The treatment group, 35 patients, will be injected with 100 units BTX-A one day following penile colour Doppler assessment.
Botulinum Toxin Type A: Drug: Botulinum Toxin Type A The treatment group will be injected with 100 units BTX-A one day following penile colour doppler assessment.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Saline Group:
The control group, 35 patients, will be injected with 1 ml normal saline one day following penile colour Doppler assessment.
Normal saline: The treatment group will be injected with 1 ml normal saline one day following penile colour doppler assessment.</description>
          </group>
        </group_list>
        <measure>
          <title>Penile Size Before Treatment</title>
          <description>Measurement of penile length before treatment:
Flaccid, stretched and erect penile length.</description>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Flaccid penile length</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.17" spread="1.73"/>
                    <measurement group_id="O2" value="10.99" spread="2.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stretched penile length</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.36" spread="1.8"/>
                    <measurement group_id="O2" value="13.4" spread="2.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erect penile length</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.17" spread="1.72"/>
                    <measurement group_id="O2" value="14.01" spread="2.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Penile Size After Treatment</title>
        <description>Measurement of penile length after treatment.</description>
        <time_frame>2 weeks after injection.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BTX-A Group</title>
            <description>Experimental: BTX-A Group The treatment group, 35 patients, will be injected with 100 units BTX-A one day following penile colour Doppler assessment.
Botulinum Toxin Type A: Drug: Botulinum Toxin Type A The treatment group will be injected with 100 units BTX-A one day following penile colour doppler assessment.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Saline Group:
The control group, 35 patients, will be injected with 1 ml normal saline one day following penile colour Doppler assessment.
Normal saline: The treatment group will be injected with 1 ml normal saline one day following penile colour doppler assessment.</description>
          </group>
        </group_list>
        <measure>
          <title>Penile Size After Treatment</title>
          <description>Measurement of penile length after treatment.</description>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>After 2 weeks flaccid</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.46" spread="1.8"/>
                    <measurement group_id="O2" value="11.01" spread="2.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After 2 weeks stretched</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.41" spread="1.78"/>
                    <measurement group_id="O2" value="13.4" spread="2.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After 2 weeks erect</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.26" spread="1.66"/>
                    <measurement group_id="O2" value="14.03" spread="2.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Penile Size After Treatment</title>
        <description>Measurement of penile length after treatment.</description>
        <time_frame>6 and 12 weeks after injection.</time_frame>
        <population>One patient was dropped out from the treatment group after 2 weeks injection.</population>
        <group_list>
          <group group_id="O1">
            <title>Botulinum Toxin Type A (BTX-A) Group</title>
            <description>Experimental: BTX-A Group The treatment group, 35 patients, will be injected with 100 units BTX-A one day following penile colour Doppler assessment.
Botulinum Toxin Type A: Drug: Botulinum Toxin Type A The treatment group will be injected with 100 units BTX-A one day following penile colour doppler assessment.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Saline Group:
The control group, 35 patients, will be injected with 1 ml normal saline one day following penile colour Doppler assessment.
Normal saline: The treatment group will be injected with 1 ml normal saline one day following penile colour doppler assessment.</description>
          </group>
        </group_list>
        <measure>
          <title>Penile Size After Treatment</title>
          <description>Measurement of penile length after treatment.</description>
          <population>One patient was dropped out from the treatment group after 2 weeks injection.</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>After 6 weeks flaccid</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.54" spread="1.83"/>
                    <measurement group_id="O2" value="10.99" spread="2.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After 6 weeks stretched</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.46" spread="1.81"/>
                    <measurement group_id="O2" value="13.4" spread="2.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After 12 weeks flaccid</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.46" spread="1.74"/>
                    <measurement group_id="O2" value="10.99" spread="2.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After 12 weeks stretched</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.44" spread="1.79"/>
                    <measurement group_id="O2" value="13.4" spread="2.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intra-vaginal Latency Time Before Treatment</title>
        <description>Measurement of the duration of intercourse from intromission to ejaculation before treatment.</description>
        <time_frame>Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BTX-A Group</title>
            <description>Experimental: BTX-A Group The treatment group, 35 patients, will be injected with 100 units BTX-A one day following penile colour Doppler assessment.
Botulinum Toxin Type A: Drug: Botulinum Toxin Type A The treatment group will be injected with 100 units BTX-A one day following penile colour doppler assessment.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Saline Group:
The control group, 35 patients, will be injected with 1 ml normal saline one day following penile colour Doppler assessment.
Normal saline: The treatment group will be injected with 1 ml normal saline one day following penile colour doppler assessment.</description>
          </group>
        </group_list>
        <measure>
          <title>Intra-vaginal Latency Time Before Treatment</title>
          <description>Measurement of the duration of intercourse from intromission to ejaculation before treatment.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IVLT less than 1 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IVLT from 1 to 3 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IVLT more than 3 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intra-vaginal Latency Time After Treatment</title>
        <description>Measurement of the duration of intercourse from intromission to ejaculation after treatment.</description>
        <time_frame>2 weeks after injection.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BTX-A Group</title>
            <description>Experimental: BTX-A Group The treatment group, 35 patients, will be injected with 100 units BTX-A one day following penile colour Doppler assessment.
Botulinum Toxin Type A: Drug: Botulinum Toxin Type A The treatment group will be injected with 100 units BTX-A one day following penile colour doppler assessment.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Saline Group:
The control group, 35 patients, will be injected with 1 ml normal saline one day following penile colour Doppler assessment.
Normal saline: The treatment group will be injected with 1 ml normal saline one day following penile colour doppler assessment.</description>
          </group>
        </group_list>
        <measure>
          <title>Intra-vaginal Latency Time After Treatment</title>
          <description>Measurement of the duration of intercourse from intromission to ejaculation after treatment.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>After 2 weeks IVLT less than 1 minute</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After 2 weeks IVLT between 1 to 3 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After 2 weeks IVLT more than 3 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intra-vaginal Latency Time After Treatment</title>
        <description>Measurement of the duration of intercourse from intromission to ejaculation after treatment.</description>
        <time_frame>6 and 12 weeks after injection.</time_frame>
        <population>One patient was dropped out from the treatment group after 2 weeks injection.</population>
        <group_list>
          <group group_id="O1">
            <title>Botulinum Toxin Type A (BTX-A) Group</title>
            <description>Experimental: BTX-A Group The treatment group, 35 patients, will be injected with 100 units BTX-A one day following penile colour Doppler assessment.
Botulinum Toxin Type A: Drug: Botulinum Toxin Type A The treatment group will be injected with 100 units BTX-A one day following penile colour doppler assessment.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Saline Group:
The control group, 35 patients, will be injected with 1 ml normal saline one day following penile colour Doppler assessment.
Normal saline: The treatment group will be injected with 1 ml normal saline one day following penile colour doppler assessment.</description>
          </group>
        </group_list>
        <measure>
          <title>Intra-vaginal Latency Time After Treatment</title>
          <description>Measurement of the duration of intercourse from intromission to ejaculation after treatment.</description>
          <population>One patient was dropped out from the treatment group after 2 weeks injection.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>After 6 weeks IVLT less than 1 minute</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After 6 weeks IVLT between 1 to 3 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After 6 weeks IVLT more than 3 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After 12 weeks IVLT less than 1 minute</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After 12 weeks IVLT between 1 to 3 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After 12 weeks IVLT more than 3 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse effects were collected at 2, 6 and12 weeks for each patient throughout the study.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>BTX-A Group</title>
          <description>Experimental: BTX-A Group The treatment group, 80 patients, will be injected with 100 units BTX-A one day following penile colour Doppler assessment.
Botulinum Toxin Type A: Drug: Botulinum Toxin Type A The treatment group will be injected with 100 units BTX-A one day following penile colour doppler assessment.</description>
        </group>
        <group group_id="E2">
          <title>Placebo Group</title>
          <description>Saline Group:
The control group, 80 patients, will be injected with 1 ml normal saline one day following penile colour Doppler assessment.
Normal saline: The treatment group will be injected with 1 ml normal saline one day following penile colour doppler assessment.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Hussein Ghanem, Directer of this clinical trial</name_or_title>
      <organization>Cairo University</organization>
      <phone>01001176111</phone>
      <email>hmhghanem@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

